Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered for primary immunisation in infants aged ≥6 weeks and as a booster in children aged ≤6 years.
DTPa-IPV — diphtheria-tetanus, acellular pertussis (DTPa) and inactivated poliovirus combination vaccine
The vaccine is a combination vaccine and consists of a monodose of 0.5 mL suspension in a vial.
Each 0.5 mL monodose pre-filled syringe contains:
- ≥30 IU Diphtheria Toxoid1
- ≥40 IU Tetanus Toxoid1
- 25 µg Pertussis Toxoid1
- 25 µg Filamentous Haemagglutinin1
- 8 µg Pertactin1
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)2
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)2
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)2
1 adsorbed onto aluminium hydroxide hydrate
2 propagated in VERO cells
Also contains traces of:
- formaldehyde
- glutaraldehyde
- polymyxin B sulfate
- neomycin sulfate
- bovine derived materials
For Product Information and Consumer Medicine Information about Infanrix IPV visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.